Ardelyx reports preliminary Q4 2023 IBSRELA net sales of ~$28M, full year ~$80M, and XPHOZAH ~$2.5M

ARDELYX, INC.

IBSRELA US net sales: Q4 ~$28M, FY2023 ~$80M (unaudited).
XPHOZAH US net sales: Q4 ~$2.5M (unaudited).
Cash and investments ~$184M as of Dec 31, 2023 (unaudited).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ARDELYX, INC. reported the fourth quarter ended December 31, 2023 results: revenue approximately $28 million.

Period: the fourth quarter ended December 31, 2023
Revenue: approximately $28 million
Result: preliminary results

Exact text from the filing

On January 8, 2024, Ardelyx, Inc. (the “Company”) announced unaudited U.S. net product sales revenue of IBSRELA ® (tenapanor) of approximately $28 million for the fourth quarter ended December 31, 2023

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ARDELYX, INC. reported the full year ended December 31, 2023 results: revenue approximately $80 million.

Period: the full year ended December 31, 2023
Revenue: approximately $80 million
Result: preliminary results

Exact text from the filing

On January 8, 2024, Ardelyx, Inc. (the “Company”) announced unaudited U.S. net product sales revenue of IBSRELA ® (tenapanor) of approximately $28 million for the fourth quarter ended December 31, 2023, and approximately $80 million for the full year ended December 31, 2023

View on SEC.gov

Browse all earnings releases →

ARDELYX, INC. filing history →

Source: SEC EDGAR

accession 0001628280-24-000772

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.